Clinical Trial Update: Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) [Phase 4]

View source ↗

Summary

Phase 4 OFELIA trial evaluating intravenous AVXS-101 (onasemnogene abeparvovec) in pediatric spinal muscular atrophy has completed with results posted, reportin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Muscular Atrophy, Spinal | Phase 4 | Status: COMPLETED | Results posted: 2024-05-31